Table 2.
Cell surface binding and transcytosis of test antibodies in MDCK cells and MDCK-FcRn cells.
| Test antibody | Transcytosis in MDCK cells (ng/mL) | Transcytosis in MDCK-hFcRn cells (ng/mL) | Clearance in humans (mL/d/kg) | Binding to MDCK cells (MFI) | Binding to MDCK-hFcRn cells (MFI) |
|---|---|---|---|---|---|
| Bevacizumab | 0.3 | 3.4 | 3.1 | 81 | 102 |
| Trastuzumab | 0.3 | 2.7 | 2.9 | 178 | 336 |
| Pertuzumab | 1.1 | 6.8 | 3.4 | 1005 | 1354 |
| Ocrelizumab | 0.5 | 4.8 | 2.4 | 78 | 101 |
| Basiliximab | 1.1 | 14.8 | 14.1 | 111 | 203 |
| Infliximab | 0.7 | 5.6 | 4.5 | 99 | 128 |
| Adalimumab | 0.5 | 4.7 | 4.1 | 77 | 183 |
| Reslizumab | 0.6 | 3.3 | 2.4 | 74 | 93 |
| mAb6 | 0.3 | 7.4 | 8.5 | 111 | 168 |
| mAb12 | 0.5 | 10.2 | 10.6 | 103 | 233 |
| No mAb | NA | NA | NA | 75 | 94 |
Transcytosis data are shown as averages of reportable values from at least two independent experiments. Cell binding activity was determined by flow cytometry. MFI = mean fluorescence intensity.